European Patent Office (EPO) has issued the patent for the world’s first and only intraocular lens produced with Sinusoidal Vision Technology (SVT) by VSY Biotechnology.
In the year 2018, with its extensive know-how and the strength of its R&D center, VSY Biotechnology introduced its next generation Sinusoidal Vision Technology by developing its conventional optical structure. An intraocular lens produced with SVT, Acriva Trinova’s sinusoidal trifocal optic design has been officially registered by the European Patent Office.
Sinusoidal Vision Technology (SVT) is a unique technology that does not have sharp steps on the optical surface of intraocular lenses (IOLs). This technology provides the best optic performance. The smoothly varying surface profile derived from the sinusoidal curve exhibits no sharp edges. The lens shape is derived from sinusoidal functions and results in smoothly varying surface profiles. Therefore ideal continuous vision is achieved as opposed to common conventional overlapping diffraction pattern trifocal IOLs with sharp edges. This sinusoidal structure also helps to minimize photic phenomena.
Acriva Trinova is the next-generation trifocal IOL designed with stepless zones as opposed to stepped zones found in the optics of conventional trifocal intraocular lenses. Twelve unique ridges on the optic surface create the highest light transmission, widest depth of focus and optimum light distribution through all pupil diameters. Moreover, Ultra Definition (UD) aspheric optic, chromatic aberration-free structure and widest depth of focus promise a spectacle independence life at all distances.